| Â | Â |
           2 October 2023
Â
           Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Â
           Director/PDMR Shareholding
Â
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces that it was notified on 28 September 2023 that on the same day, Individual Savings Accounts ("ISA's") held in the name of Liz Shanahan, Non-Executive Director, purchased 19,755 ordinary shares of 5p each ("Ordinary Shares") at a price of 198.64p per Ordinary Share and ISA's held by Timothy Lacey, husband and a PCA of Liz Shanahan, purchased 30,586 Ordinary Shares at a price of 198.64p per Ordinary Share.
Â
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Â
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
Â
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||||
| a) | Name:  (i) Liz Shanahan            (ii) Timothy Lacey | ||||||
2. | Reason for the notification | ||||||
| a) | Position/status:            (i) Director                        (ii) PCA to Liz Shanahan, Non-Executive Director | ||||||
| b) | Initial notification/Amendment: Initial Notification | ||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a) | Name:Â Â Advanced Medical Solutions Group plc | ||||||
| b) | LEI: 213800HJP6OWOSZI1L74 | ||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||||
| b) | Nature of the transactions: ·     Purchase of Ordinary Shares | ||||||
| c) | Price(s) and volume(s):
| ||||||
| d) | Aggregated information: N/A | ||||||
| e) | Date of the transaction: 28/09/2023 | ||||||
| f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
Â
Â
- End -
Â
For further information, please visit www.admedsol.com or contact:
Â
| Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
| Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations | |
| | Â |
| ICR Consilium | Tel: +44 (0) 20 3709 5700 |
| Matthew Neal / Lucy Featherstone | AMS@consilium-comms.com |
| | |
| Investec Bank PLC (NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
| Gary Clarence / David Anderson | Â Â |
| HSBC Bank plc (Broker) | Tel: 44 (0) 20 7991 8888 |
| Sam McLennan / Joe Weaving / Stephanie Cornish | |
Â
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made five acquisitions: Sealantis, an Israeli developer of innovative internal sealants; Biomatlante, a French developer and manufacturer of surgical biomaterials, Raleigh, a leading UK coater and converter of woundcare and bio-diagnostics materials, AFS Medical, an Austrian specialist surgical business and Connexicon, an Irish tissue adhesives specialist.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Ireland, Germany, France and Israel. Established in 1991, the Group has more than 800 employees. For more information, please see  www.admedsol.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.